Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
Science
; 351(6279): 1339-42, 2016 Mar 18.
Article
in En
| MEDLINE
| ID: mdl-26917593
ABSTRACT
Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25 to 90%. There is no licensed treatment or vaccine against the virus, underscoring the need for efficacious countermeasures. We ascertained that a human survivor of the 1995 Kikwit Ebola virus disease outbreak maintained circulating antibodies against the Ebola virus surface glycoprotein for more than a decade after infection. From this survivor we isolated monoclonal antibodies (mAbs) that neutralize recent and previous outbreak variants of Ebola virus and mediate antibody-dependent cell-mediated cytotoxicity in vitro. Strikingly, monotherapy with mAb114 protected macaques when given as late as 5 days after challenge. Treatment with a single human mAb suggests that a simplified therapeutic strategy for human Ebola infection may be possible.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hemorrhagic Fever, Ebola
/
Ebolavirus
/
Antibodies, Neutralizing
/
Antibodies, Monoclonal
/
Antibodies, Viral
Limits:
Adult
/
Animals
/
Female
/
Humans
/
Male
Language:
En
Journal:
Science
Year:
2016
Type:
Article
Affiliation country:
Switzerland